[1] |
张建中. 特应性皮炎的诊断标准发展及评价[J]. 中华皮肤科杂志, 2017,50(1):67⁃69. doi: 10.3760/cma.j.issn.0412⁃4030. 2017.01.025.
|
[2] |
Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China[J]. J Eur Acad Dermatol Venereol, 2020,34(3):542⁃548. doi: 10.1111/jdv.15979.
|
[3] |
Guo Y, Zhang H, Liu Q, et al. Phenotypic analysis of atopic dermatitis in children aged 1⁃12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence[J]. J Eur Acad Dermatol Venereol, 2019,33(8):1569⁃1576. doi: 10.1111/jdv.15618.
|
[4] |
Ständer S. Atopic dermatitis[J]. N Engl J Med, 2021,384(12):1136⁃1143. doi: 10.1056/NEJMra2023911.
|
[5] |
Blauvelt A, de Bruin⁃Weller M, Gooderham M, et al. Long⁃term management of moderate⁃to⁃severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1⁃year, randomised, double⁃blinded, placebo⁃controlled, phase 3 trial[J]. Lancet, 2017,389(10086):2287⁃2303. doi: 10.1016/S0140⁃6736(17)31191⁃1.
|
[6] |
Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016,375(24):2335⁃2348. doi: 10.1056/NEJMoa 1610020.
|
[7] |
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial[J]. JAMA Dermatol, 2020,156(1):44⁃56. doi: 10.1001/jamadermatol. 2019.3336.
|
[8] |
Clot PF, Kamal M, Sun J, et al. Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: results of two randomized, double⁃blind, placebo⁃controlled studies[J]. Int Immunopharmacol, 2021,99:107985. doi: 10.1016/ j.intimp.2021.107985.
|
[9] |
顾建青, 高翔, 孙劲旅, 等.度普利尤单抗治疗中重度特应性皮炎初步临床观察 [J]. 中华临床免疫和变态反应杂志, 2021,15(4):370⁃375. doi: 10.3969/j.issn.1673⁃8705.2021.04. 003.
|
[10] |
刘擘, 宋晓婷, 李若瑜, 等. 度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022,55(4):295⁃298. doi:10.35541/cjd.20210736.
|
[11] |
Zhou BJ, Peng C, Li LQ, et al. Efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a real⁃world study[J]. Front Med (Lausanne), 2022,9:838030. doi: 10.3389/fmed.2022. 838030.
|
[12] |
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis[J]. N Engl J Med, 2014,371(2):130⁃139. doi: 10.1056/NEJMoa1314768.
|
[13] |
Zhao Y, Wu L, Lu Q, et al. The efficacy and safety of dupilumab in Chinese patients with moderate⁃to⁃severe atopic dermatitis: a randomized, double⁃blind, placebo⁃controlled study[J]. Br J Dermatol, 2022,186(4):633⁃641. doi: 10.1111/bjd.20690.
|
[14] |
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double⁃blinded, placebo⁃controlled phase 3 trial[J]. J Am Acad Dermatol, 2020,83(5):1282⁃1293. doi: 10.1016/j.jaad.2020.06. 054.
|
[15] |
Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab[J]. JAAD Case Rep, 2019,5(5):471⁃473. doi: 10.1016/j.jdcr.2019.03.016.
|
[16] |
Schneeweiss MC, Kim SC, Wyss R, et al. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score⁃matched cohort study[J]. J Am Acad Dermatol, 2021,84(2):300⁃311. doi: 10.1016/j.jaad.2020. 09.084.
|
[17] |
Treister AD, Kraff⁃Cooper C, Lio PA. Risk factors for dupilumab⁃associated conjunctivitis in patients with atopic dermatitis[J]. JAMA Dermatol, 2018,154(10):1208⁃1211. doi: 10.1001/jamadermatol.2018.2690.
|
[18] |
Akinlade B, Guttman⁃Yassky E, de Bruin⁃Weller M, et al. Conjunctivitis in dupilumab clinical trials[J]. Br J Dermatol, 2019,181(3):459⁃473. doi: 10.1111/bjd.17869.
|
[19] |
Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review[J]. J Am Acad Dermatol, 2021,84(5):1339⁃1347. doi: 10.1016/j.jaad.2021.01.012.
|
[20] |
Muzumdar S, Zubkov M, Waldman R, et al. Characterizing dupilumab facial redness in children and adolescents: a single⁃institution retrospective chart review[J]. J Am Acad Dermatol, 2020,83(5):1520⁃1521. doi: 10.1016/j.jaad.2020.06.1003.
|
[21] |
Gao DX, Song S, Kahn JS, et al. Treatment of patients experiencing dupilumab facial redness with itraconazole and fluconazole: a single⁃institutional, retrospective medical record review[J]. J Am Acad Dermatol, 2022,86(4):938⁃940. doi: 10. 1016/j.jaad.2021.03.070.
|
[22] |
de Wijs L, Nguyen NT, Kunkeler A, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series[J]. Br J Dermatol, 2020,183(4):745⁃749. doi: 10.1111/bjd.18730.
|
[23] |
Magro CM, Scheck L, Soleymani AD. Unmasking of a TH1⁃mediated vitiligo⁃like tendency in the setting of dupilumab therapy for adult atopic dermatitis[J]. The Dermatologist, 2020,28(4):22⁃24.
|
[24] |
Takeoka S, Kamata M, Yokoi I, et al. Rapid enlargement of vitiligo vulgaris after initiation of dupilumab for atopic dermatitis: a case report[J]. Acta Derm Venereol, 2021,101(10):adv00581. doi: 10.2340/actadv.v101.545.
|
[25] |
Cerminara C, El⁃Malhany N, Roberto D, et al. Seizures induced by desloratadine, a second⁃generation antihistamine: clinical observations[J]. Neuropediatrics, 2013,44(4):222⁃224. doi: 10. 1055/s⁃0033⁃1333871.
|